keyword
MENU ▼
Read by QxMD icon Read
search

Nsabp cancer

keyword
https://www.readbyqxmd.com/read/29768301/germline-genome-wide-association-studies-in-women-receiving-neoadjuvant-chemotherapy-with-or-without-bevacizumab
#1
James N Ingle, Krishna R Kalari, Donald Lawrence Wickerham, Gunter von Minckwitz, Peter A Fasching, Yoichi Furukawa, Taisei Mushiroda, Matthew P Goetz, Poulami Barman, Erin E Carlson, Priya Rastogi, Joseph P Costantino, Junmei Cairns, Soonmyung Paik, Harry D Bear, Michiaki Kubo, Liewei Wang, Norman Wolmark, Richard M Weinshilboum
Neoadjuvant chemotherapy (NAC) for breast cancer is widely utilized, and we performed genome-wide association studies (GWAS) to determine whether germ-line genetic variability was associated with benefit in terms of pathological complete response (pCR), disease-free survival, and overall survival in patients entered on the NSABP B-40 NAC trial, wherein patients were randomized to receive, or not, bevacizumab in addition to chemotherapy. Patient DNA samples were genotyped with the Illumina OmniExpress BeadChip...
June 2018: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/29704066/current-status-of-extended-adjuvant-endocrine-therapy-in-early-stage-breast-cancer
#2
REVIEW
Irene E G van Hellemond, Sandra M E Geurts, Vivianne C G Tjan-Heijnen
In the past decade, several endocrine treatment regimens have been developed for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, including tamoxifen, aromatase inhibitors (AI), or a combination of these. The standard duration of adjuvant endocrine treatment has been 5 years for a long time. Nevertheless, the high number of recurrences occurring after 5 years suggested that extended endocrine therapy could further improve outcome, which led to the start of several randomized clinical trials investigating the effects of extended use of endocrine therapy...
April 27, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29695917/four-cycles-of-adriamycin-and-cyclophosphamide-followed-by-four-cycles-of-docetaxel-nsabp-b27-with-concomitant-trastuzumab-as-neoadjuvant-therapy-for-high-risk-early-stage-her2-positive-breast-cancer-patients
#3
Hikmat Abdel-Razeq, Salwa S Saadeh, Mahmoud Abu-Nasser, Hazem Abdulelah, Lina Marie, Murad Salam, Basel Al-Haj Ali, Mohammad Ibrahim, Dalia Rimawi
Background: The majority of breast cancer patients in Jordan are diagnosed at a young age and present with metastatic or locally advanced disease. The National Surgical Adjuvant Breast and Bowel Project Protocol B27 (NSABP-B27) (four cycles of adriamycin and cyclophosphamide [AC] followed by four cycles of docetaxel) is a standard neoadjuvant regimen in our institution. In this study, we report the efficacy of adding trastuzumab to docetaxel in this regimen for high-risk human epidermal growth factor receptor 2 (HER2)-positive early-stage disease...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29399271/extended-adjuvant-aromatase-inhibitor-therapy-in-post-menopausal-women
#4
Stephen M Schleicher, Maura N Dickler
Purpose of the review: To understand the evidence for extending adjuvant aromatase inhibitor (AI) therapy from 5 to 10 years in post-menopausal women with hormone receptor positive (HR+) breast cancer. Recent findings: Multiple large trials have investigated this question. The two trials most representative of the dilemma faced in clinical practice are the MA.17R and NSABP-B42 trials, which both investigated the benefit of continuing versus stopping AI therapy beyond 5 years...
December 2017: Current Breast Cancer Reports
https://www.readbyqxmd.com/read/29383405/individualization-of-post-mastectomy-radiotherapy-and-regional-nodal-irradiation-based-on-treatment-response-after-neoadjuvant-chemotherapy-for-breast-cancer-a-systematic-review
#5
David Krug, René Baumann, Wilfried Budach, Jürgen Dunst, Petra Feyer, Rainer Fietkau, Wulf Haase, Wolfgang Harms, Thomas Hehr, Marc D Piroth, Felix Sedlmayer, Rainer Souchon, Frederik Wenz, Rolf Sauer
PURPOSE: To review the evidence regarding post-mastectomy radiotherapy (PMRT) and regional nodal irradiation (RNI) after neoadjuvant chemotherapy (NACT) for breast cancer, with a special focus on individualization of adjuvant radiotherapy based on treatment response. METHODS: A systematic literature search using the PubMed/Medline database was performed. We included prospective and retrospective reports with a minimum of 10 patients that had been published since 1st  January 2000, and provided clinical outcome data analyzed by treatment response and radiotherapy...
January 30, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29241223/tumour-sidedness-and-intrinsic-subtypes-in-patients-with-stage-ii-iii-colon-cancer-analysis-of-nsabp-c-07-nrg-oncology
#6
S Rim Kim, Nan Song, Greg Yothers, Patrick G Gavin, Carmen J Allegra, Soonmyung Paik, Katherine L Pogue-Geile
BACKGROUND: We tested the association of colon tumour sidedness with prognosis and with molecular subtypes recently shown to be predictive of oxaliplatin benefit in stage III colon cancer. METHODS: NSABP/NRG C-07 trial (N=1603) was used to determine association of tumour sidedness with molecular subtypes and recurrence-free survival (RFS) and overall survival (OS). RESULTS: Sidedness was associated with molecular subtypes except stem-like/CMS4 subtype...
March 6, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29128898/21-gene-recurrence-score-for-prognosis-and-prediction-of-taxane-benefit-after-adjuvant-chemotherapy-plus-endocrine-therapy-results-from-nsabp-b-28-nrg-oncology
#7
Eleftherios P Mamounas, Gong Tang, Soonmyung Paik, Frederick L Baehner, Qing Liu, Jong-Hyeon Jeong, S Rim Kim, Steven M Butler, Farid Jamshidian, Diana B Cherbavaz, Amy P Sing, Steven Shak, Thomas B Julian, Barry C Lembersky, D Lawrence Wickerham, Joseph P Costantino, Norman Wolmark
BACKGROUND: The 21-gene recurrence score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated the 21-gene RS for its prognostic impact and its ability to predict benefit from paclitaxel (P) in node-positive, estrogen receptor-positive (ER+) breast cancer patients treated with adjuvant chemotherapy plus tamoxifen. METHODS: The B-28 trial compared doxorubicin/cyclophosphamide (AC) with AC followed by P in 3060 patients...
February 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29072977/long-term-follow-up-of-cardiac-function-and-quality-of-life-for-patients-in-nsabp-protocol-b-31-nrg-oncology-a-randomized-trial-comparing-the-safety-and-efficacy-of-doxorubicin-and-cyclophosphamide-ac-followed-by-paclitaxel-with-ac-followed-by-paclitaxel-and
#8
RANDOMIZED CONTROLLED TRIAL
Patricia A Ganz, Edward H Romond, Reena S Cecchini, Priya Rastogi, Charles E Geyer, Sandra M Swain, Jong-Hyeon Jeong, Louis Fehrenbacher, Howard M Gross, Adam M Brufsky, Patrick J Flynn, Tanya A Wahl, Thomas E Seay, James L Wade, David D Biggs, James N Atkins, Jonathan Polikoff, John L Zapas, Eleftherios P Mamounas, Norman Wolmark
Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and health-related quality of life are lacking in long-term follow-up of patients who remain cancer free after completion of adjuvant treatment. Patients and Methods Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast cancer...
December 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28968398/snps-near-the-cysteine-proteinase-cathepsin-o-gene-ctso-determine-tamoxifen-sensitivity-in-er%C3%AE-positive-breast-cancer-through-regulation-of-brca1
#9
Junmei Cairns, James N Ingle, Lawrence D Wickerham, Richard Weinshilboum, Mohan Liu, Liewei Wang
Tamoxifen is one of the most commonly employed endocrine therapies for patients with estrogen receptor α (ERα)-positive breast cancer. Unfortunately the clinical benefit is limited due to intrinsic and acquired drug resistance. We previously reported a genome-wide association study that identified common SNPs near the CTSO gene and in ZNF423 associated with development of breast cancer during tamoxifen therapy in the NSABP P-1 and P-2 breast cancer prevention trials. Here, we have investigated their roles in ERα-positive breast cancer growth and tamoxifen response, focusing on the mechanism of CTSO...
October 2017: PLoS Genetics
https://www.readbyqxmd.com/read/28954297/long-term-peripheral-neuropathy-in-breast-cancer-patients-treated-with-adjuvant-chemotherapy-nrg-oncology-nsabp-b-30
#10
RANDOMIZED CONTROLLED TRIAL
Hanna Bandos, Joy Melnikow, Donna R Rivera, Sandra M Swain, Keren Sturtz, Louis Fehrenbacher, James L Wade, Adam M Brufsky, Thomas B Julian, Richard G Margolese, Edward C McCarron, Patricia A Ganz
Background: The long-term effects of chemotherapy are sparsely reported. Peripheral neuropathy (PN) is one of the most frequent toxicities associated with taxane use for the treatment of early-stage breast cancer. We investigated the impact of the three different docetaxel-based regimens and patient characteristics on long-term, patient-reported outcomes of PN and the impact of PN on long-term quality of life (QOL). Methods: The National Surgical Adjuvant Breast and Bowel Project Protocol B-30 was a randomized trial comparing sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T) (AC→T), concurrent ACT, or AT in women with node-positive, early-stage breast cancer...
February 1, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28856246/breast-cancer-chemoprevention-pharmacogenomics-deep-sequencing-and-functional-genomics-of-the-znf423-and-ctso-genes
#11
Duan Liu, Ming-Fen Ho, Daniel J Schaid, Steven E Scherer, Krishna Kalari, Mohan Liu, Joanna Biernacka, Vivien Yee, Jared Evans, Erin Carlson, Matthew P Goetz, Michiaki Kubo, D Lawrence Wickerham, Liewei Wang, James N Ingle, Richard M Weinshilboum
Our previous GWAS using samples from the NSABP P-1 and P-2 selective estrogen receptor modulator (SERM) breast cancer prevention trials identified SNPs in ZNF423 and near CTSO that were associated with breast cancer risk during SERM chemoprevention. We have now performed Next Generation DNA sequencing to identify additional SNPs that might contribute to breast cancer risk and to extend our observation that SNPs located hundreds of bp from estrogen response elements (EREs) can alter estrogen receptor alpha (ERα) binding in a SERM-dependent fashion...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/28667456/from-clinical-trials-to-clinical-practice-outcome-of-nsabp-b27-neoadjuvant-chemotherapy-regimen-for-high-risk-early-stage-breast-cancer
#12
Hikmat Abdel-Razeq, Lina Marei, Salwa S Saadeh, Hazem Abdulelah, Mahmoud Abu-Nasser, Mourad Salam, Walid Daana, Basel Al-Haj Ali, Ayat Taqash
PURPOSE: Majority of Jordanian breast cancer patients present at a relatively young age and with locally advanced disease highlight the importance of neoadjuvant chemotherapy. This study evaluated the efficacy and safety of NSABP-B27 regimen in high-risk patients in daily clinical practice. METHODS: Patients' medical records and hospital database were searched for all consecutive patients treated at our institution for breast cancer using neoadjuvant NSABP-B27 chemotherapy regimen...
October 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28666922/controversies-in-treatment-selection-for-patients-with-equivocal-er-and-her2-results
#13
Giuseppe Viale
Formally, the term "equivocal" should not be used when reporting results of the assessment of ER status, but controversies exist about the prognostic and predictive value of a low ER expression (i.e. 1-9% positive cells) in breast cancer (so called ER-poor tumors). Because of the rarity of these cases, prospective clinical trials have not been conducted (and are unlikely to be conducted in the future) to define the optimal treatment strategy for the small subset of patients with ER-poor breast cancer. Therefore, the only available data stem from retrospective subgroup analyses of randomized clinical trials or from clinical datasets of individual Institutions...
August 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28661894/exploring-explanatory-models-of-risk-in-breast-cancer-risk-counseling-discussions-nsabp-nrg-oncology-decision-making-project-1
#14
Christine M Gunn, Barbara Bokhour, Victoria A Parker, Patricia A Parker, Sarah Blakeslee, Hanna Bandos, Christine Holmberg
BACKGROUND: Explanatory models represent patient understanding of etiology, pathophysiology, illness, symptoms, and treatments, but little attention has been paid to how they are used by patients "at risk" for future disease. OBJECTIVE: The aims of this study were to elucidate what constitutes an explanatory model of risk and to describe explanatory models of risk related to developing breast cancer. METHODS: Thirty qualitative interviews with women identified as at an increased risk for breast cancer were conducted...
June 28, 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28624048/comparison-of-two-different-types-of-oxidized-regenerated-cellulose-for-partial-breast-defects
#15
COMPARATIVE STUDY
Jeeyeon Lee, Jin Hyang Jung, Wan Wook Kim, Jung Dug Yang, Jeong Woo Lee, Junjie Li, Ho Yong Park
BACKGROUND: A defect after partial mastectomy, sometimes, is hard to be filled with patient's own breast tissue. Two different types of oxidized regenerated cellulose (ORC) for filling of partial defects in small-sized breasts were compared with respect to clinicopathologic factors and outcomes. METHODS: A total of 45 patients with breast cancer underwent conventional partial mastectomy with insertion of an ORC filling material. The two filling materials used were a hemostasis-purposed ORC and adhesion barrier-purposed ORC...
June 15, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28581400/first-results-of-a-phase-2-trial-of-once-weekly-hypofractionated-breast-irradiation-whbi-for-early-stage-breast-cancer
#16
Anthony E Dragun, Nicholas J Ajkay, Elizabeth C Riley, Teresa L Roberts, Jianmin Pan, Shesh N Rai, Dharamvir Jain, Amy R Quillo, Charles R Scoggins, Kelly M McMasters, Shiao Y Woo
PURPOSE: To report early outcome analysis of a prospective institutional phase 2 trial of weekly hypofractionated breast irradiation (WHBI) for patients undergoing breast-conserving surgery (BCS). METHODS AND MATERIALS: Patients who underwent BCS for American Joint Committee on Cancer stage 0, I, or II breast cancer with negative surgical margins received whole-breast radiation therapy to 30 or 28.5 Gy in 5 weekly fractions with or without an additional boost. The eligibility criteria were the same as for NSABP (National Surgical Adjuvant Breast and Bowel Project) B39/RTOG (Radiation Therapy Oncology Group) 0413, and there were no restrictions on age, breast size, tumor grade, receptor status, or the use of cytotoxic chemotherapy for otherwise eligible patients...
July 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28447237/effects-of-metformin-versus-placebo-on-vitamin-b12-metabolism-in-non-diabetic-breast-cancer-patients-in-cctg-ma-32
#17
Ana Elisa Lohmann, Mira F Liebman, William Brien, Wendy R Parulekar, Karen A Gelmon, Lois E Shepherd, Jennifer A Ligibel, Dawn L Hershman, Priya Rastogi, Ingrid A Mayer, Timothy J Hobday, Julie Lemieux, Alastair Mark Thompson, Kathleen I Pritchard, Timothy Joseph Whelan, Som D Mukherjee, Haji I Chalchal, Vanessa Bernstein, Vuk Stambolic, Bingshu E Chen, Pamela Jean Goodwin
BACKGROUND: Metformin is associated with low levels of vitamin B12 (VitB12) in patients with diabetes. The CCTG/MA.32 trial investigates the effects of metformin vs placebo on breast cancer (BC) outcomes in non-diabetic high-risk BC patients. We analyzed VitB12 at baseline and after 6 months of metformin (versus placebo) in the first 492 patients with paired blood samples. METHODS: VitB12 was analyzed centrally in baseline and 6-month fasting plasma. Levels <181 pmol/L were considered deficient, 181-221 pmol/L borderline, and ≥222 pmol/L sufficient...
July 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28398846/anthracyclines-in-early-breast-cancer-the-abc-trials-usor-06-090-nsabp-b-46-i-usor-07132-and-nsabp-b-49-nrg-oncology
#18
RANDOMIZED CONTROLLED TRIAL
Joanne L Blum, Patrick J Flynn, Greg Yothers, Lina Asmar, Charles E Geyer, Samuel A Jacobs, Nicholas J Robert, Judith O Hopkins, Joyce A O'Shaughnessy, Chau T Dang, Henry Leonidas Gómez, Louis Fehrenbacher, Svetislava J Vukelja, Alan P Lyss, Devchand Paul, Adam M Brufsky, Jong-Hyeon Jeong, Linda H Colangelo, Sandra M Swain, Eleftherios P Mamounas, Stephen E Jones, Norman Wolmark
Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin and cyclophosphamide (AC) in a trial in early breast cancer. However, activity of TC relative to AC regimens with a taxane (TaxAC) is unknown. Methods In a series of three adjuvant trials, women were randomly assigned to TC for six cycles (TC6) or to a standard TaxAC regimen. US Oncology Research (USOR) 06-090 compared TC6 with docetaxel, doxorubicin, and cyclophosphamide (TAC6). National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132 compared TC6, TAC6, or TC6 plus bevacizumab...
August 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28285537/milestone-clinical-trials-of-the-national-surgical-adjuvant-breast-and-bowel-project-nsabp
#19
REVIEW
Priya Rastogi, D Lawrence Wickerham, Charles E Geyer, Eleftherios P Mamounas, Thomas B Julian, Norman Wolmark
The National Surgical Adjuvant Breast and Bowel Project (NSABP) has made significant contributions in reducing the extent of breast surgery and in improving outcomes of patients with early-stage breast cancer through the conduct of large randomized clinical trials evaluating local and systemic therapy. In 2014, the NSABP merged with two other US National Cancer Institute-funded cooperative groups, the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG), to form NRG Oncology. The combined organization has 218 member institutions with more than 600 affiliate centers located throughout the United States, Canada, Puerto Rico, and other international sites...
February 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28094211/likelihood-of-unacceptable-normal-tissue-doses-in-breast-cancer-patients-undergoing-regional-nodal-irradiation-in-routine-clinical-practice
#20
Jose Bazan, Dominic DiCostanzo, Karla Kuhn, Lonika Majithia, Allison Quick, Nilendu Gupta, Julia White
PURPOSE: As indications for regional nodal irradiation (RNI) for breast cancer have expanded, so too has scrutiny over potential late toxicity from radiotherapy. This emphasizes the need for careful radiation treatment planning to maximize the therapeutic ratio. We sought to evaluate how often unacceptable doses (UDs) to organs at risk (OARs) occur and the associated factors for patients receiving RNI in daily practice. METHODS AND MATERIALS: Treatment records of patients who received RNI from February 2012 to May 2015 were studied...
May 2017: Practical Radiation Oncology
keyword
keyword
73971
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"